Study Design
DesignRandomized, double-blind, placebo and active-controlled
Randomization3:1:1
BlindingDouble-blind
Enrollment506
Duration52 weeks
Treatment Arms
Risankizumab 150mg 150mg SC at Wk 0,4 then q12w n=304
Ustekinumab 45/90mg 45/90mg SC weight-based q12w n=100
Placebo Placebo → risankizumab at Wk 16 n=102
[{"id":"pasi90-w16","name":"PASI 90 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":75.3,"arm_id":"risnk-arm","p_value":0.001},{"value":42,"arm_id":"ust-arm"},{"value":4.9,"arm_id":"pbo-arm"}],"timepoint":"Week 16","description":"Near-complete clearance. KEY result establishing Skyrizi superiority over Stelara."}]
Established Skyrizi dominance over Stelara. PASI 90 gap: 33 pts at Wk16, widened to 38 pts at Wk52. Deepening response is evidence of TRM17 depletion. Cleanest safety in class — no candidiasis signal.